C
Candid Therapeutics
Biotech & Life Sciences · San Diego, United States · Founded 2024
A clinical-stage biotech firm focused on advancing treatments for a range of immunological conditions MoreLess
CandidRx is a biotechnology company focused on developing innovative therapies for autoimmune diseases. The company leverages known biological mechanisms to create novel, easy-to-administer treatments that offer significant benefits to patients. CandidRx operates in the healthcare and life sciences market, primarily serving patients suffering from autoimmune conditions. The company's business model revolves around rigorous scientific research and the development of T cell engager antibodies, which precisely redirect T cells to selectively eliminate autoreactive B cells, aiming for transformative efficacy and safety. Revenue is generated through the development and commercialization of these therapies, supported by investments from prominent stakeholders who share the company's vision. CandidRx's team comprises industry experts with a proven track record in creating stakeholder value. The company is committed to advancing the field of autoimmune therapy through its pioneering approach and deep understanding of immunological mechanisms.
Keywords: autoimmune diseases, T cell engager antibodies, biotechnology, novel therapies, immunological mechanisms, healthcare, life sciences, scientific research, stakeholder value, innovative treatments.
Company overview
Candid Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2024
- Headquarters
- San Diego, United States
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 92.8
- Investment activity
- 1 companies · latest Mar 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Candid Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2026 | $2B | $2B | UCB | ↗ |
| LATE VCOther financing | Sep 2024 | $370M | $1.5B | Polaris Partners · Fidelity Investments · Foresite Capital · Franklin Templeton Investments | ↗ |
Growth signals
Candid Therapeutics website traffic
Latest recorded traffic for Candid Therapeutics is 3.9K monthly website visits, down 37.1% over the last three months. Candid Therapeutics's team grew 0% over the past year.
Comparisons
Candid Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Candid Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Candid Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Candid Therapeutics has talent and traffic
team presence
In the news
Latest news about Candid Therapeutics
Recent press, funding announcements, and product moves mentioning Candid Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Candid Therapeutics
An AI-synthesized read of the highest-engagement posts about Candid Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Candid Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.


























